This site is intended for our International customers. If you wish to visit our US site, please choose your appropriate region using the selector in the top right of this page.

Icon / Search Created with Sketch.
Icon / Close Created with Sketch.


Introducing MosaiQ™ by Quotient

Better matched blood = better patient care.

MosaiQ will be the world’s first fully-automated testing solution that will allow for rapid, extensive antigen typing and antibody identification of donor and patient blood utilizing a single microarray. The extended phenotyping capabilities will enable better matched blood and reduced risk of alloimmunization. This will in turn provide patients with timely delivery of safe and compatible blood products.

Operating on a fully automated, consolidated platform, MosaiQ will offer the potential for improved clinical decision making and considerable operating efficiencies, both in a donor and patient testing environments.



Designed to be a comprehensive automated testing solution with the goal to establish new standards of excellence in transfusion medicine worldwide.

The MosaiQ platform has the goal of enabling:

  • Comprehensive characterization of donor blood using just a single blood sample
  • Increased workflow efficiencies through walk-away-capable processing of 1000 microarrays in a single 8-hour shift
  • Enhanced resource management capabilities from a platform designed for ease of use, simplified reagent and consumable needs
  • Reliable and reproducible results 


MosaiQ™ Overview

Designed to become the world’s first fully automated and integrated testing platform for both blood grouping and transfusion transmitted infectious disease screening of donated blood, MosaiQ will harness a mix of traditional serology and advanced microarray technology.

MosaiQ™ Benefits

MosaiQ is being developed to meet customer needs.

MosaiQ™ Technology

Learn more about the powerful microarray technology at the heart of MosaiQ.